Efficacy of sildenafil as adjuvant therapy to selective serotonin reuptake inhibitor in alleviating premature ejaculation

Urology. 2003 Jan;61(1):197-200. doi: 10.1016/s0090-4295(02)02075-7.

Abstract

Objectives: To evaluate the efficacy of sildenafil and selective serotonin reuptake inhibitor in alleviating premature ejaculation (PE) in patients in whom other treatments had failed.

Methods: Healthy men evaluated for primary PE graded their ejaculation on a scale of 0 to 8 (0 = almost never, 8 = almost always). The intravaginal ejaculatory latency time (IVELT) was graded on a scale of 0 to 3 (0 = longer than 5 minutes, 3 = shorter than 1 minute). The 138 men who scored their PE as 4 or greater and IVELT as 2 or greater comprised the study group. Psychological and behavioral counseling was provided during the study. PE was graded using the same scales 3 months after the initiation of each treatment. Topical 5% lidocaine ointment comprised the initial treatment: dissatisfied patients (PE grade 4 or greater, IVELT 2 or greater), took one tablet of paroxetine 20 mg for 30 days and then one tablet 7 hours before intercourse. Sildenafil was added to the treatment of patients dissatisfied with paroxetine alone.

Results: The mean initial PE grade was 5.67 +/- 0.13 and that for IVELT was 2.9 +/- 0.19 for all participants (mean age 28.7 years). Thirty-eight reported improvement (PE grade 2.0 +/- 0.8, P <0.01; IVELT 0.13 +/- 0.34, P <0.001) after local lidocaine application. Of the 100 treated with paroxetine, 42 reported improvement (PE grade 2.5 +/- 0.1, P <0.01; IVELT 0.28 +/- 0.46, P <0.001), and 56 of the remaining 58 who were treated with a combination of paroxetine and sildenafil reported improvement (PE grade 1.78 +/- 0.23, P <0.001; IVELT 0.16 +/- 0.37, P <0.001). Two patients remained dissatisfied with all treatment modalities.

Conclusions: Sildenafil combined with paroxetine and psychological and behavioral counseling alleviated PE in patients in whom other treatments failed.

Publication types

  • Comparative Study

MeSH terms

  • Administration, Topical
  • Adolescent
  • Adult
  • Drug Therapy, Combination
  • Ejaculation / drug effects*
  • Humans
  • Lidocaine / therapeutic use
  • Male
  • Paroxetine / therapeutic use*
  • Penis / drug effects
  • Phosphodiesterase Inhibitors / pharmacology
  • Phosphodiesterase Inhibitors / therapeutic use*
  • Piperazines / pharmacology
  • Piperazines / therapeutic use*
  • Purines
  • Selective Serotonin Reuptake Inhibitors / therapeutic use*
  • Sex Counseling
  • Sexual Dysfunction, Physiological / drug therapy*
  • Sildenafil Citrate
  • Sulfones
  • Treatment Outcome

Substances

  • Phosphodiesterase Inhibitors
  • Piperazines
  • Purines
  • Serotonin Uptake Inhibitors
  • Sulfones
  • Paroxetine
  • Lidocaine
  • Sildenafil Citrate